Key facts
- It has raised $30.0M; the latest was Early Stage VC ($30.0M) in Aug 2025.
- Notable investors include Catalio Capital Management.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Ospri
- ·The full record, as it builds
Funding rounds
No funding rounds for Ospri are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ospri
Developer of molecular diagnostic technologies designed to streamline and improve operational efficiency in laboratory testing. The company offers proprietary direct-to-PCR assays with extraction-free workflows, advanced multiplexing, and scalable lab operations, allowing doctors and laboratory researchers to cut testing time, reduce complexity, and enable high-throughput pathogen detection, empowering healthcare systems to deliver faster, more cost-effective diagnostics.
- Sector
- Healthcare
- HQ
- McKinney, TX, United States
- Founded
- 2025
- Website
- ospribio.com/
- Ownership
- Privately Held (backing)
Ospri doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ospri shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ospri in its N-PORT filings yet. We sweep new filings monthly.